world
GSK to Reverse Oncology Exit With Largest Acquisition in Eight Years
The company is buying a cancer-focused business in its biggest deal since 2018, reversing an earlier decision to exit the field.
MA
benzinga.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
GSK announced its largest acquisition in eight years, a move aimed at rebuilding its cancer portfolio after previously winding down those operations. The purchase marks a reversal of GSK's earlier strategy to exit oncology. Company statements indicate the deal is intended to accelerate growth in cancer treatments.
@MarketWatch reported the transaction as GSK's biggest purchase since 2018. The announcement provides no additional financial terms or timeline for closing.
Transparency
1 source · single source
CorroborationModerate · 1 source
